Back to search results

Nectero EAST System for Abdominal Aortic Aneurysm

This study is testing a new treatment called the Nectero EAST System for people with small to medium-sized abdominal aortic aneurysms (AAA), which are bulges in the main artery that carries blood from your heart. The treatment involves a single, local delivery of the Stabilizer Infusion Solution (drug) through a procedure. Researchers want to see if this treatment can stop the AAA from growing, compared to the usual approach of just watching it. You may be able to join if you are between 21 and 85 years old and have an AAA between 3.5 cm and 5.0 cm. The study aims to show the treatment's effectiveness over 24 months. The current recruitment status is unclear.

Study design
This is a randomized clinical trial planning to enroll 400 participants. It will compare the Nectero EAST System treatment to standard care.
What's involved
You would undergo an endovascular procedure with the Nectero EAST System and receive the Stabilizer Infusion Solution. You would have follow-up visits at 30/60 days, 6, 12, 18, and 24 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 24 months for the primary endpoint, with continued annual follow-up for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06001918

Nectero EAST System Clinical Study

Recruiting
PHASE2Ages 21–85InterventionalTreatment
Nectero Medical, Inc.
~400 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Nectero EAST System

At a glance

Recruiting sites
33 of 39 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Endpoint
Measured over 24 months

Conditions

Abdominal Aortic Aneurysm

Explore related trials

Abdominal Aortic Aneurysm

Where it's being run

39 sites across 28 states
Ohio5
Pennsylvania4
Massachusetts3
New York2
Texas2
Arizona1
Colorado1
District of Columbia1

Study leadership

  • Daniel Clair, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
  • Grace Wang, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania

Who to contact

Charlene Knape
[email protected]
866-755-4744
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Primary Endpoint24 months

    The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm).